Context Therapeutics - Women’s oncology play with a novel pipeline
Context Therapeutics is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications. Lead program onapristone extended release (ONA-XR) is a potential first-in-class progesterone receptor (PR) antagonist being evaluated in several mid-stage clinical programs in advanced breast, endometrial and ovarian cancer, all areas with significant unmet need. In-licensing a bi-specific monoclonal antibody, CLDN6Xcd3, in April 2021 has added another (preclinical) novel compound to the pipeline. With multiple data readouts expected in 2022, we foresee several inflection points in the coming months. We initiate coverage with a valuation of $134.9m or $8.45/share.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.